Tales from the Road: AI Innovators on their Fundraising Journey

Thursday November 18, 1:00PM EST

Hear from fundraising entrepreneurs on their processes researching, pitching, and working with investors. AI technology has incredible potential in healthcare, but also raises unique challenges. Hear from founders on how AI fits into their story and solutions, and how they sourced the right investors for them.

Panelists:

Request a Meeting

DJ (Dennis) Schmitt, Founder/CEO, Neuro20 Technologies

DJ is a former 2nd Force Recon Marine with a 50% disability from his service. He served as a High Threat/Low Profile personal protection specialist for multiple government agencies (OGA). During his time in service, he earned a BS in Engineering. Utilizing his leadership, team building skills, and his vast network of relationships, DJ put his discipline and drive to work and became a serial entrepreneur after his service ended. He built the number one defense contracting ISP company in Southwest Asia serving NATO forces. Upon a successful exit from this venture, he returned to the Unites States where he continued with his entrepreneurial spirit, owning, and operating multiple successful small businesses through his holdings company until he founded Neuro20 technologies in January 2021.  

Request a Meeting

Sangeeta Agarawal, CEO and co-founder, Helpsy Health

Sangeeta has been a software engineer for over 10 years at companies such as IBM and Motorola/Google. She is also an oncology researcher and an advanced certified nurse at Mayo Clinic, Stanford, and UCSF. She is the Founder, CEO, and the vision behind Helpsy Health.

Request a Meeting

Jonathan Cohen, CEO, 20/20 GeneSystems

Jonathan Cohen is the Founder, President, and CEO of 20/20 GeneSystems. Under Mr. Cohen’s leadership, 20/20 has brought in approximately $7.5 million in grant funding and launched two successful products, a bio-detection kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer. He is the Co-Inventor of an AI approach for improving tumor biomarker accuracy that is covered in a pending pct international patent application.

Request a Meeting

Lana Feng, Co-Founder & CEO, HumaAI Inc

Dr. Lana Feng is the co-founder and CEO of Huma.AI. She has over 20 years of experience in biotech and pharmaceutical industries, mostly in precision medicine. Dr. Feng came from Novartis Oncology Business Unit where she established international partnerships for their precision medicine programs. She joined Novartis through its acquisition of Genoptix. Dr. Feng built the BioPharma division at Genoptix, where she grew the business from zero to $45M in five years by forging alliances with pharmaceutical companies and providing CDx development for targeted therapies. The division was instrumental in Genoptix’ acquisition by Novartis for $500M. Prior to Genoptix, Dr. Feng was an early employee and held key positions at GeneOhm Sciences, which was acquired by Becton Dickinson for $300M, and Nanogen which went public in 1998. Dr. Feng is a member of Bayhelix, an organization of global healthcare leaders of Chinese heritage. She was the winner of the BRAVO Rising Star Award from the National Association of Women Business Owners (NAWBO), and Industry Innovation Award from Blossom Ventures presented at the annual Women’s Entrepreneurship Summit.